FDA Approved: VYZULTA — Original Application (Bausch & Lomb Incorporated)

View source ↗

Summary

FDA approved VYZULTA (latanoprostene bunod), from Bausch & Lomb, as a new treatment for open-angle glaucoma and ocular hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• VYZULTA (latanoprostene bunod)

Snippet

ORIG AP for VYZULTA (LATANOPROSTENE BUNOD)